Sarah Sammons, Breast Medical Oncologist at Dana-Farber’s Breast Oncology Center, shared a post on X/Twitter:
“To my academic colleagues,
When rendering a 2nd opinion that is different from a patients local oncologist, it should be data driven/implementable. If not FDA approved, the pt should be alerted to possible access issues. Message From,
My non-academic brilliant Med Onc friends”
When rendering a 2nd opinion that is different from a patients local oncologist, it should be data driven/implementable. If not FDA approved, the pt should be alerted to possible access issues. Message From,
My non-academic brilliant Med Onc friends”
Source: Sarah Sammons/X